ARTICLE | Management Tracks
Capstan names Turning Point’s Countouriotis as chair
Plus updates from Vor, Osivax, Alvotech and Roth
October 12, 2022 9:38 PM UTC
Cell engineering company Capstan Therapeutics Inc. named Athena Countouriotis as chair and Michael Rosenzweig as EVP of portfolio strategy and product development. Countouriotis was president and CEO of Turning Point Therapeutics Inc., which was recently acquired by Bristol Myers Squibb Co. (NYSE:BMY) for $4.1 billion. Rosenzweig was an entrepreneur in residence at RA Ventures.
Cell and genome engineering company Vor Biopharma Inc. (NASDAQ:VOR) hired Eyal Attar as CMO. Attar was SVP and CMO at Aprea Therapeutics Inc. (NASDAQ:APRE), before which he was senior medical director at Agios Pharmaceuticals Inc. (NASDAQ:AGIO)...